Advanced Practice Midwife in Roswell, NM Accepting Medicare

4 Advanced Practice Midwife nurses found. Showing 1 - 4

Mrs. Katrina Nicole Kelly, CNM Advanced Practice Midwife Medicare: Accepting Medicare Assignments Practice Location: 350 W Country Club Rd Ste 203, Roswell, NM 88201 Phone: 575-624-4646    Fax: 575-625-8498

Katrina Dowdy, CNM Advanced Practice Midwife Medicare: Medicare Enrolled Practice Location: 1112 N Main St, Roswell, NM 88201 Phone: 575-627-4200

Chad Emerson Rumsey, APRN, CNM Advanced Practice Midwife Medicare: Medicare Enrolled Practice Location: 305 W Country Club Rd, Roswell, NM 88201 Phone: 575-622-6322    Fax: 575-622-6322

Callie M Dodson, CNM Advanced Practice Midwife Medicare: Not Enrolled in Medicare Practice Location: 305 W Country Club Rd, Roswell, NM 88201 Phone: 575-622-6322    Fax: 575-622-6888

News Archive

E.coli scare in UK now affects nine people

The E.coli outbreak in Paisley, Scotland has now affected nine people; one woman has died and three more remain in a serious condition while the other five are said to be recovering.

High prevalence of infection with three recently discovered human polyomaviruses

A majority of the human population has been exposed to newly discovered KI (KIV), WU (WUV), and Merkel cell (MCV) human polyomaviruses, according to a new study by researchers at the University of Colorado.

Toshiba's new V-TRACE MRA for brain imaging

When imaging the brain, time is critical as vascular abnormalities can have a profound effect on patients' lives if not diagnosed quickly. To help health care facilities diagnose disease with greater accuracy and speed, Toshiba America Medical Systems, Inc. has introduced Variable True Rate Angiography with Combined Encodings, an exclusive MRA sequence available on all Vantage TitanTM and Vantage Atlas® MR systems.

Treatment for HBV infection with entecavir followed by lamivudine results in virologic rebound

A two-year trial of entecavir followed by lamivudine (LAM) in patients with chronic hepatitis B virus (HBV) infection resulted in a virologic rebound rate of 24% and 12% drug-resistance rate. Patients who continued on entecavir therapy throughout the study period had undetectable HBV DNA at the two-year endpoint. Details of this trial are published in the April issue of Hepatology, a journal published by Wiley-Blackwell on behalf of the American Association for the Study of Liver Diseases.

Read more Medical News

› Verified 1 days ago